Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 3, 2005, Pages 366-370

  Moayyeri, Alireza ^a,b   Daryani, Naser Ebrahimi ^a   Bahrami, Hossein ^a   Haghpanah, Babak ^a   Nayyer Habibi, Atoosa ^a   Sadatsafavi, Mohsen ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Iran)

Author keywords

Case control study; Clinical course; Colorectal cancer; Primary sclerosing cholangitis; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COLITIS; COLON DISEASE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOLOGY; HOSPITALIZATION; HUMAN; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 16344366021     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03727.x     Document Type: Article

References (25)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology Practice Parameters Committee. Am. J. Gastroenterol. 1997; 2: 204-11.
2. Ardizzone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. J. Intern. Med. 2002; 6: 475-96.
3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. BMJ 1955; 2: 1041-8.
4. Bitton A, Sewitch MJ, Peppercorn MA et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am. J. Gastroenterol. 2003; 10: 2203-8.
5. Kaufmann HJ, Taubin HL. Non-steroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann. Intern. Med. 1987; 4: 513-16.
6. Moum B, Aadland E, Ekbom A, Vatn MH. Seasonal variations in the onset of ulcerative colitis. Gut 1996; 3: 376-8.
7. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N. Engl. J. Med. 1995; 14: 924-33.
8. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999; 1: 325-32.
9. Tung BY, Brentnall T, Kowdley KV et al. Diagnosis and prevalence of ulcerative colitis in patients with sclerosing cholangitis (Abstract). Hepatology 1996; 24: 169A.
10. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 1999; 6: 1643-9.
11. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997; 4: 522-5.
12. Selby W. The natural history of ulcerative colitis. Baillieres Clin. Gastroenterol. 1997; 1: 53-64.
13. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 1: 3-11.
14. Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Pre-cancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990; 7: 800-6.
15. Gurbuz AK, Giardiello FM, Bayless TM. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis. Colon Rectum 1995; 1: 37-41.
16. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 5: 1404-8.
17. Aadland E, Schrumpf E, Fausa O et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 1987; 22: 655-64.
18. Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis. Colon Rectum 1997; 4: 451-6.
19. Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 5: 639-44.
20. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am. J. Gastroenterol. 1992; 8: 971-6.
21. Olsson R, Danielsson A, Jarnerot G et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 5: 1319-23.
22. Hashimoto E, Ideta M, Taniai M et al. Prevalence of primary sclerosing cholangitis and other liver diseases in Japanese patients with chronic ulcerative colitis. J. Gastroenterol. Hepatol. 1993; 2: 146-9.
23. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest. Endosc. 2002; 56: 48-54.
24. Collins RH, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N. Engl. J. Med. 1987; 26: 1654-8.
25. Gyde SN, Prior P, Allan RN; et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centers. Gut 1988; 2: 206-17.